Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178749 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anna A Barinova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Cell Differentiation, Diabetes Mellitus, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus (DM) is a metabolic disease characterized by persistent hyperglycemia, resulting from defects in insulin secretion or impaired insulin action. In cases of severe pancreatic cell dysfunction and deficiency, the primary treatment remains lifelong insulin injections. A potential alternative is allogeneic pancreatic cell transplantation from a donor, which can stabilize glucose levels. However, the scarcity of donor material and the risk of immune rejection limit the widespread use of this approach. An alternative solution involves using in vitro-derived insulin-producing cells generated through the differentiation of pluripotent stem cells (PSCs), which could overcome the shortage of transplantable material. Furthermore, patient-specific cells—obtained directly from the patient via reprogramming of blood or skin cells into induced pluripotent stem cells (iPSCs)—would avoid immune rejection. Advances in this field have led to the active development and optimization of PSC differentiation into hormone-producing cells worldwide, with more than hundred patients dosed in clinical trials with ESC-derived cells and the single trial of iPSC-derived cells. This review highlights recent progress and prospects in generating insulin-producing cells from human PSCs, their applications in therapy development and disease modeling, as well as the current challenges and potential solutions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.
- Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
- Vavilov Institute of General Genetics, Russian Academy of Sciences, 117971 Moscow, Russia.
ORCID-Profile: Anna A Barinova, Alexandra N Bogomazova, Alyona A Borisova
Förderung
- Russian Science Foundation
Zitieren
APA
Barinova, A. A., Bogomolova, A. Y., Bogomazova, A. N., Borisova, A. A., Kiselev, S. L., & Panova, A. V. (2025). Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178749
Vancouver
Barinova AA, Bogomolova AY, Bogomazova AN, Borisova AA, Kiselev SL, Panova AV. Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178749
BibTeX
@article{Barinova2025,
author = {Barinova, Anna A and Bogomolova, Alexandra Y and Bogomazova, Alexandra N and Borisova, Alyona A and Kiselev, Sergey L and Panova, Alexandra V},
title = {Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178749}
}
EUVIMED